10.08  0.05 (0.5%)		03-02 16:00
Open: 9.96 High: 10.59 Volume: 183,662		Pre. Close: 10.03 Low: 9.5 Market Cap: 806(M)

Short term
Mid term
Targets	6-month :	14.33	1-year :	16.34
Resists	First :	12.27	Second :	13.98
Pivot price	10.58
Supports	First :	9.5	Second :	7.9
MAs	MA(5) :	10.19	MA(20) :	10.76
	MA(100) :	11.84	MA(250) :	11.14
MACD	MACD :	-0.5	Signal :	-0.5
%K %D	K(14,3) :	15.9	D(3) :	16.6
RSI	RSI(14): 40
52-week	High :	14.86	Low :	8.5

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ BBOT ] has closed above bottom band by 27.9%. Bollinger Bands are 3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	10.59 - 10.66	10.66 - 10.72
Low:	9.36 - 9.43	9.43 - 9.5
Close:	9.97 - 10.08	10.08 - 10.18

BridgeBio Oncology Therapeutics is a clinical-stage biopharmaceutical company developing next-generation small molecule therapeutics targeting RAS and PI3Kα malignancies, which are prevalent oncogenes in human tumors. Initially formed as a subsidiary of BridgeBio Pharma, it focuses on precision oncology with a pipeline that includes BBO-8520, BBO-10203, and BBO-11818 programs targeting KRAS and PI3K pathways. The company recently went public through a business combination with Helix Acquisition Corp. II, raising approximately $450 million to advance clinical development. The CEO is Dr. Eli Wallace, and the CSO is Dr. Pedro Beltran.

Wed, 25 Feb 2026
BBOT: Novel RAS-targeted therapies show strong efficacy and safety, with major data readouts expected soon - TradingView

Wed, 25 Feb 2026
HLXB SEC Filings - Helix Acqsn II 10-K, 10-Q, 8-K Forms - Stock Titan

Thu, 12 Feb 2026
BBOT to Participate in Upcoming Investor Healthcare Conferences - Sahm

Wed, 11 Feb 2026
BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Wed, 11 Feb 2026
Stifel Initiates Coverage of BridgeBio Oncology Therapeutics (BBOT) with Buy Recommendation - Nasdaq

Tue, 10 Feb 2026
Stifel initiates coverage on BridgeBio Oncology stock with Buy rating - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	80 (M)
Shares Float	31 (M)
Held by Insiders	27 (%)
Held by Institutions	69.8 (%)
Shares Short	2,160 (K)
Shares Short P.Month	1,850 (K)

EPS	-1.46
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	5.63
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.56
Qtrly Earnings Growth	0 %
Operating Cash Flow	-87 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	-6.96
PEG Ratio	0
Price to Book value	1.78
Price to Sales	0
Price to Cash Flow	-9.31

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.